Primary relevance to vitamin D Vitamin D is a stated subject of this paper.
Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.
Why this paper is included
Supporting source evidence:
The aim of this current study was to examine if daily vitamin D3 supplementation (cholecalciferol, 1000 IU/day) in pregnancy suppresses hepcidin concentration and/or affects iron body stores (ferritin) and inflammation (CRP and α1-acid glycoprotein (AGP)) compared to placebo.
Source: 1. Introduction. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Randomised controlled trial.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Meta-analysis unclear · Double-blind reported · Human research reported
Reported blinded roles: participants.
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Using a subset of the UK multicenter Maternal Vitamin D Osteoporosis Study (MAVIDOS): a double-blinded, randomized, placebo-controlled trial (ISRCTN82927713; EudraCT2007-001716-23): we performed a secondary laboratory analysis.
Source: Abstract.
Using a subset of the UK multicenter Maternal Vitamin D Osteoporosis Study (MAVIDOS): a double-blinded, randomized, placebo-controlled trial (ISRCTN82927713; EudraCT2007-001716-23): we performed a secondary laboratory analysis.
Source: Abstract.
Women were screened for vitamin D status, and only those with 25OHD concentrations between 25 and 100 nmol/L and who were not currently taking dietary supplements with more than 400 IU of vitamin D/day were eligible.
Source: Methods.
Randomization was achieved by a computer-generated sequence in randomly permuted blocks of ten, and both the participants and research team were masked to treatment allocation.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
The Effect of Vitamin D Supplementation on Hepcidin, Iron Status, and Inflammation in Pregnant Women in the United Kingdom
Randomised controlled trial · Nutrients · 2019
Original publication title
The Effect of Vitamin D Supplementation on Hepcidin, Iron Status, and Inflammation in Pregnant Women in the United Kingdom
© 2019 by the authors.
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
What does the authors’ abstract report?
Iron and vitamin D deficiencies are common during pregnancy. Our aim was to identify whether antenatal vitamin D3 supplementation affects iron status (via hepcidin suppression) and/or inflammation. Using a subset of the UK multicenter Maternal Vitamin D Osteoporosis Study (MAVIDOS): a double-blinded, randomized, placebo-controlled trial (ISRCTN82927713; EudraCT2007-001716-23): we performed a secondary laboratory analysis. Women with blood samples from early and late pregnancy (vitamin D3 (1000 IU/day from ~14 weeks gestation n = 93; placebo n = 102) who gave birth in the springtime (March: May) were selected as we anticipated seeing the greatest treatment group difference in change in 25-hydroxyvitamin D (25OHD) concentration.
Outcomes were hepcidin, ferritin, C-reactive protein, and α1-acid glycoprotein concentration in late pregnancy (25OHD concentration was measured previously). By late pregnancy, 25OHD concentration increased by 17 nmol/L in the vitamin D3 group and decreased by 11 nmol/L in the placebo group; hepcidin, ferritin, and inflammatory markers decreased but no treatment group differences were seen. In late pregnancy, positive relationships between 25OHD and hepcidin and 25OHD and ferritin in the placebo group were observed but not in the treatment group (group × 25OHD interaction, p < 0.02).
Vitamin D3 supplementation had no effect on hepcidin, ferritin, or inflammatory status suggesting no adjunctive value of vitamin D3 in reducing rates of antenatal iron deficiency.
Authors’ abstract
Iron and vitamin D deficiencies are common during pregnancy. Our aim was to identify whether antenatal vitamin D3 supplementation affects iron status (via hepcidin suppression) and/or inflammation. Using a subset of the UK multicenter Maternal Vitamin D Osteoporosis Study (MAVIDOS): a double-blinded, randomized, placebo-controlled trial (ISRCTN82927713; EudraCT2007-001716-23): we performed a secondary laboratory analysis. Women with blood samples from early and late pregnancy (vitamin D3 (1000 IU/day from ~14 weeks gestation n = 93; placebo n = 102) who gave birth in the springtime (March: May) were selected as we anticipated seeing the greatest treatment group difference in change in 25-hydroxyvitamin D (25OHD) concentration.
Outcomes were hepcidin, ferritin, C-reactive protein, and α1-acid glycoprotein concentration in late pregnancy (25OHD concentration was measured previously). By late pregnancy, 25OHD concentration increased by 17 nmol/L in the vitamin D3 group and decreased by 11 nmol/L in the placebo group; hepcidin, ferritin, and inflammatory markers decreased but no treatment group differences were seen. In late pregnancy, positive relationships between 25OHD and hepcidin and 25OHD and ferritin in the placebo group were observed but not in the treatment group (group × 25OHD interaction, p < 0.02).
Vitamin D3 supplementation had no effect on hepcidin, ferritin, or inflammatory status suggesting no adjunctive value of vitamin D3 in reducing rates of antenatal iron deficiency.
Publication and source details
Original title: The Effect of Vitamin D Supplementation on Hepcidin, Iron Status, and Inflammation in Pregnant Women in the United Kingdom
Vickie S. Braithwaite; Sarah R. Crozier; Stefania D’Angelo; Ann Prentice; Cyrus Cooper; Nicholas C. Harvey; Kerry S. Jones; the MAVIDOS Trial Group
Nutrients · 2019
* Correspondence: vb287@cam.ac.ukCurrent address: MRC Nutrition and Bone Health Research Group, Clifford Allbutt Building, University of Cambridge, Cambridge CB2 0AH, UK.
Membership of the MAVIDOS Trial Group is provided in the Acknowledgments.
Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T04:08:44.446200+00:00
DOI: 10.3390/nu11010190 · PMC6356300